16 completed, 8 unknown, 7 recruiting, 5 not yet recruiting. 13 Phase 2, 7 Phase 1, 6 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Urinary Bladder Cancer: new trials by email Literature Review of Urinary Bladder Cancer trials Research Report on Urinary Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies Metastatic Urothelial Carcinoma, Urothelial Cancer | Not yet recruiting | Pfizer | 5122 | 2026-10-21 | 2026-10-27 | |
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma Trastuzumab Rezetecan plus Camrelizumab - Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Sheng Tai | 44 | 2026-06-05 | 2026-06-10 |
| SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel) - Urinary Bladder Cancer, Upper Tract Urothelial Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 28 | 2026-03-06 | 2026-05-06 |
| Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer Gemcitabine and Cisplatin (DD GC) - Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Assiut University | 30 | 2025-09-01 | 2025-09-19 |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Riluzole, Placebo - Breast Cancer, Sarcoma | Phase 2 | Recruiting | University of California, Irvine | 75 | 2024-12-02 | 2026-07-14 |
| Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor Cognitive Decline, Urinary Bladder Cancer | Recruiting | Osijek University Hospital | 42 | 2024-11-28 | 2025-09-10 | |
| Predictive Role of Microbiome in Patients With Urothelial Carcinoma DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood. - Urinary Bladder Cancer | Not yet recruiting | IRCCS San Raffaele | 420 | 2024-11-01 | 2024-11-05 | |
| Enhanced Assistance During Radiotherapy for Unmet Essential Needs Standard assistance, Enhanced assistance - Bone Cancer, Brain Cancer | Not applicable | Completed | Washington University School of Medicine | 33 | 2024-10-04 | 2025-08-26 |
| Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors. En bloc TURBT using a bipolar Karl-Storz resectoscope system fitted with a specialized "flat" resection loop, Bipolar piecemeal TURBT using the same bipolar Karl-Storz resectoscopic platform - Urinary Bladder Cancer | Not applicable | Completed | Ain Shams University | 50 | 2024-08-01 | 2025-12-10 |
| Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients Lung Ultrasound - guided Stepwise PEEP, Standard Ventilation Protocol - Prostate Cancer, Urinary Bladder Cancer | Not applicable | Completed | Nazmy Edward Seif | 88 | 2024-04-01 | 2026-10-20 |
| Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection MRI - Urinary Bladder Cancer | Unknown | Assiut University | 58 | 2023-04-01 | 2023-03-28 | |
| Intravesical Gem/Doce in Patients With NMIBC gemcitabine + docetaxel - Urinary Bladder Cancer | Phase 2 | Active not recruiting | University of Arizona | 31 | 2023-03-01 | 2026-10-26 |
| Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Carboplatin-Gemcitabine Cisplatin-Gemcitabine - Urinary Bladder Cancer | Phase 3 | Unknown | Assiut University | 20 | 2022-11-01 | 2024-07-30 |
| Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy Urinary Bladder Cancer | Withdrawn | University of Kansas Medical Center | 2022-09-14 | 2024-02-28 | ||
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy MDSC quantification - Melanoma, Breast Cancer | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1000 | 2022-03-10 | 2025-05-02 | |
| Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer Pembrolizumab - Bladder Cancer, Bladder Neoplasms | Phase 2 | Recruiting | Peking University First Hospital | 54 | 2021-12-07 | 2022-01-10 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin - Urinary Bladder Cancer | Phase 2 | Recruiting | Zhujiang Hospital | 41 | 2021-06-03 | 2026-10-09 |
| Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma Chemoradiation - Urinary Bladder Cancer | Unknown | Assiut University | 50 | 2021-04-01 | 2021-03-23 | |
| Multimodal Spectroscopy to Detect Urothelial Cancer in Urine Urinary Multimodal Fiber Optic Spectroscopy, Urine Cytology, Surgery - Urothelial Carcinoma, Urinary Bladder Cancer | Unknown | University of Florence | 500 | 2021-01-28 | 2022-05-09 |
Showing 20 of 42. Sign in to see all of them.
Urinary Bladder Neoplasms (42) · Breast Neoplasms (5) · Prostatic Neoplasms (5) · Melanoma (4) · Carcinoma, Transitional Cell (3) · Head and Neck Neoplasms (3) · Lung Neoplasms (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Stomach Neoplasms (3) · Urologic Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2)
Female Urogenital Diseases (42) · Female Urogenital Diseases and Pregnancy Complications (42) · Male Urogenital Diseases (42) · Urogenital Diseases (42) · Neoplasms by Site (41) · Urinary Bladder Diseases (41) · Urologic Diseases (41) · Urogenital Neoplasms (40) · Neoplasms (39) · Urologic Neoplasms (39) · Neoplasms by Histologic Type (9) · Genital Diseases (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Carcinoma (6)
Gemcitabine (4) · Nivolumab (3) · Cisplatin (2) · Cystectomy (2) · Docetaxel (2) · Mitomycin (2) · Adjuvants, Pharmaceutic (1) · Administration, Intravesical (1) · Capecitabine (1) · Chemoradiotherapy (1) · Defecation (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Neoadjuvant Therapy (1) · Panitumumab (1)
Assiut University (6) · Ain Shams University (2) · Copenhagen University Hospital, Rigshospitalet (2) · Taris Biomedical LLC (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · AstraZeneca (1) · BioNTech US Inc. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · IRCCS San Raffaele (1) · Karolinska Institutet (1) · Lahey Clinic (1) · Mansoura University (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Medical Enterprises Europe B.V. (1) · Medical Enterprises Ltd. (1)
United States (11) · Egypt (7) · China (4) · Netherlands (4) · Canada (3) · Italy (3) · Denmark (2) · Germany (2) · Austria (1) · Croatia (1) · Israel (1) · Sudan (1) · Sweden (1)
Abai Xu, doctor (1) · Adriaan D. Bins, MD PhD (1) · Alexandre Chan, PharmD, MPH (1) · Alfred A Witjes, MD PhD (1) · Amal Rayan, Professor (1) · Amr Farouk Muorad, Prof.Doctor (1) · Ashgan R Ali, MD (1) · David Hong, MD (1) · Donald Lamm, MD, FACS (1) · Dorthe Skovgaard, MD, PhD (1) · Dorthe Skovgaard, MD, Phd (1) · Enrico Baria, PhD (1) · Francesco Saverio Pavone, Prof (1) · Franco Carli, MD (1) · Gabriella Nesi, Prof (1)
PMID 12118019, PMID 22213823, PMID 22998907, PMID 23052535, PMID 24613684, PMID 26803476, PMID 27001593, PMID 31900121, PMID 31910427, PMID 32002290, PMID 33064988, PMID 33294862, PMID 33617327, PMID 35431132, PMID 36624315, PMID 38022709, PMID 39048933, PMID 39692276, PMID 7953264, PMID 9681889
2009 (1), 2014 (1), 2016 (1)